Apr 19, 2026Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Mar 23, 2026Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsPresentation / Abstract • Phase 1
Dec 3, 2025Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid TumorsTrial Start • Phase 1
